Molecular therapies and precision medicine for hepatocellular carcinoma

Home | About RECERCAT | Contact

Català | Castellano

All of RECERCAT

By Communities &
Collections By Defense Date By Authors By Titles By Subject

This Collection

By Defense Date By Authors By Titles By Subject

Statistics

View Statistics All RECERCAT

My RECERCAT

Other repositories directory

RECERCAT Home > Universitat de Barcelona > IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer > Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) > View document

To access the full text documents, please follow this link: http://hdl.handle.net/2445/127373

dc.contributor.author	Llovet i Bayer, Josep Maria
dc.contributor.author	Montal, Robert
dc.contributor.author	Sia, Daniela
dc.contributor.author	Finn, Richard S.
dc.date	2019-01-17T11:24:27Z
dc.date	2019-07-30T05:10:19Z
dc.date	2018-07-30
dc.identifier	3984320
dc.identifier.uri	http://hdl.handle.net/2445/127373
dc.description	The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass an annual incidence of 1 million cases. Genomic studies have established the landscape of molecular alterations in HCC; however, the most common mutations are not actionable, and only ~25% of tumours harbour potentially targetable drivers. Despite the fact that surveillance programmes lead to early diagnosis in 40–50% of patients, at a point when potentially curative treatments are applicable, almost half of all patients with HCC ultimately receive systemic therapies. Sorafenib was the first systemic therapy approved for patients with advanced-stage HCC, after a landmark study revealed an improvement in median overall survival from 8 to 11 months. New drugs — lenvatinib in the frontline and regorafenib, cabozantinib, and ramucirumab in the second line — have also been demonstrated to improve clinical outcomes, although the median overall survival remains ~1 year; thus, therapeutic breakthroughs are still needed. Immune-checkpoint inhibitors are now being incorporated into the HCC treatment armamentarium and combinations of molecularly targeted therapies with immunotherapies are emerging as tools to boost the immune response. Research on biomarkers of a response or primary resistance to immunotherapies is also advancing. Herein, we summarize the molecular targets and therapies for the management of HCC and discuss the advancements expected in the near future, including biomarker-driven treatments and immunotherapies.
dc.format	18 p.
dc.format	application/pdf
dc.language	eng
dc.publisher	Nature Publishing Group
dc.relation	Versió postprint del document publicat a: https://doi.org/10.1038/s41571-018-0073-4
dc.relation	Nature Reviews Clinical Oncology, 2018, vol. 15, p. 599-616
dc.relation	https://doi.org/10.1038/s41571-018-0073-4
dc.relation	info:eu-repo/grantAgreement/EC/H2020/667273/EU//HEP-CAR
dc.rights	(c) Llovet i Bayer et al., 2018
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	Càncer de fetge
dc.subject	Immunoteràpia
dc.subject	Liver cancer
dc.subject	Immunotherapy
dc.title	Molecular therapies and precision medicine for hepatocellular carcinoma
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/acceptedVersion

Show simple item record

All of RECERCAT

This Collection

Statistics

My RECERCAT

Related documents

Other documents of the same author